SCHEMBL15699079

SCHEMBL15699079

Cc1c(Br)c(Br)c2c3c1nc(Cl)n3CCC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 3/20 0.60
CDK19 Q9BWU1 2/20 0.60
CCNC P24863 2/20 0.60
CYP1A2 P05177 1/20 0.60
CSNK2A2 P19784 1/20 0.60
CCNA2 P20248 1/20 0.60
CCNE1 P24864 1/20 0.60
CDK2 P24941 1/20 0.60
CSNK1A1 P48729 1/20 0.60
CLK1 P49759 1/20 0.60
CLK2 P49760 1/20 0.60
CDK7 P50613 1/20 0.60
CDK9 P50750 1/20 0.60
CCNH P51946 1/20 0.60
MNAT1 P51948 1/20 0.60
CDK5 Q00535 1/20 0.60
KCNH2 Q12809 1/20 0.60
ROCK1 Q13464 1/20 0.60
DYRK1A Q13627 1/20 0.60
CDK5R1 Q15078 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18602089 0.91 CDK8 (0.50) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL17106008 0.88 CDK8 (0.50) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL18602159 0.87 CDK8 (0.47) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL18602552 0.83 CDK8 (0.41) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL17106013 0.82 CDK8 (0.41) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL15699114 0.82 CDK8 (0.41) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL18602299 0.81 CDK8 (0.41) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL18602168 0.81 CDK8 (0.41) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL15699107 0.79 CDK8 (0.81) CDK8CDK19CCNCCYP1A2CSNK2A2
SCHEMBL15699111 0.78 CDK8 (0.79) CDK8CDK19CCNCCYP1A2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2015-10-01 US disclosed
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2015-10-01 US disclosed
WO-2014072435-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2014-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS CDK8, CDK18, CDK9 CDK8 1/4885CDK19 20/4885CCNC 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.